Literature DB >> 25063356

Treatment of HIV in the CNS: effects of antiretroviral therapy and the promise of non-antiretroviral therapeutics.

Michael J Peluso1, Serena Spudich.   

Abstract

The growing recognition of the burden of neurologic disease associated with HIV infection in the last decade has led to renewed efforts to characterize the pathophysiology of the virus within the central nervous system (CNS). The concept of the AIDS-dementia complex is now better understood as a spectrum of HIV-associated neurocognitive disorders (HAND), which range from asymptomatic disease to severe impairment. Recent work has shown that even optimally treated patients can experience not only persistent HAND, but also the development of new neurologic abnormalities despite viral suppression. This has thrown into question what the impact of antiretroviral therapy has been on the incidence and prevalence of neurocognitive dysfunction. In this context, the last few years have seen a concentrated effort to identify the effects that antiretroviral therapy has on the neurologic manifestations of HIV and to develop therapeutic modalities that might specifically alter the trajectory of HIV within the CNS.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25063356     DOI: 10.1007/s11904-014-0223-y

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  88 in total

1.  Cerebrospinal fluid markers in central nervous system HIV infection and AIDS dementia complex.

Authors:  Paola Cinque; Bruce J Brew; Magnus Gisslen; Lars Hagberg; Richard W Price
Journal:  Handb Clin Neurol       Date:  2007

2.  Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir.

Authors:  Brookie M Best; Scott L Letendre; Peter Koopmans; Steven S Rossi; David B Clifford; Ann C Collier; Benjamin B Gelman; Christina M Marra; Justin C McArthur; J Allen McCutchan; Susan Morgello; David M Simpson; Edmund V Capparelli; Ronald J Ellis; Igor Grant
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-01       Impact factor: 3.731

3.  Quantitative neuropathologic correlates of changes in ratio of N-acetylaspartate to creatine in macaque brain.

Authors:  Margaret R Lentz; John P Kim; Susan V Westmoreland; Jane B Greco; Robert A Fuller; Eva M Ratai; Julian He; Prabhat K Sehgal; Elkan F Halpern; Andrew A Lackner; Eliezer Masliah; R Gilberto González
Journal:  Radiology       Date:  2005-03-29       Impact factor: 11.105

4.  Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.

Authors:  Asa Mellgren; Andrea Antinori; Paola Cinque; Richard W Price; Christian Eggers; Lars Hagberg; Magnus Gisslén
Journal:  Antivir Ther       Date:  2005

5.  Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot study.

Authors:  J C Probasco; S S Spudich; J Critchfield; E Lee; N Lollo; S G Deeks; R W Price
Journal:  Neurology       Date:  2008-08-12       Impact factor: 9.910

6.  Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.

Authors:  Luis B Tovar-y-Romo; Namandjé N Bumpus; Daniel Pomerantz; Lindsay B Avery; Ned Sacktor; Justin C McArthur; Norman J Haughey
Journal:  J Pharmacol Exp Ther       Date:  2012-09-13       Impact factor: 4.030

7.  Reduced basal transcriptional activity of central nervous system-derived HIV type 1 long terminal repeats.

Authors:  Lachlan R Gray; Daniel Cowley; Emma Crespan; Casey Welsh; Charlene Mackenzie; Steve L Wesselingh; Paul R Gorry; Melissa J Churchill
Journal:  AIDS Res Hum Retroviruses       Date:  2012-09-25       Impact factor: 2.205

8.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Authors:  Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis
Journal:  Arch Neurol       Date:  2008-01

9.  Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment.

Authors:  Serena S Spudich; Annelie C Nilsson; Nicole D Lollo; Teri J Liegler; Christos J Petropoulos; Steven G Deeks; Ellen E Paxinos; Richard W Price
Journal:  BMC Infect Dis       Date:  2005-11-02       Impact factor: 3.090

10.  Disrupted cerebral metabolite levels and lower nadir CD4 + counts are linked to brain volume deficits in 210 HIV-infected patients on stable treatment.

Authors:  Xue Hua; Christina P Boyle; Jaroslaw Harezlak; David F Tate; Constantin T Yiannoutsos; Ron Cohen; Giovanni Schifitto; Assawin Gongvatana; Jianhui Zhong; Tong Zhu; Michael J Taylor; Thomas B Campbell; Eric S Daar; Jeffry R Alger; Elyse Singer; Steve Buchthal; Arthur W Toga; Bradford Navia; Paul M Thompson
Journal:  Neuroimage Clin       Date:  2013-08-03       Impact factor: 4.881

View more
  6 in total

Review 1.  Neurologic Complications in Treated HIV-1 Infection.

Authors:  Nisha S Bhatia; Felicia C Chow
Journal:  Curr Neurol Neurosci Rep       Date:  2016-07       Impact factor: 5.081

Review 2.  Neuropathogenesis of HIV: from initial neuroinvasion to HIV-associated neurocognitive disorder (HAND).

Authors:  Zaina Zayyad; Serena Spudich
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

3.  Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients.

Authors:  A Calcagno; C Atzori; A Romito; D Vai; S Audagnotto; M L Stella; C Montrucchio; D Imperiale; G Di Perri; S Bonora
Journal:  J Neurovirol       Date:  2015-08-06       Impact factor: 2.643

4.  Teriflunomide and monomethylfumarate target HIV-induced neuroinflammation and neurotoxicity.

Authors:  Björn Ambrosius; Simon Faissner; Kirsten Guse; Marec von Lehe; Thomas Grunwald; Ralf Gold; Bastian Grewe; Andrew Chan
Journal:  J Neuroinflammation       Date:  2017-03-11       Impact factor: 8.322

Review 5.  Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients.

Authors:  Jean-Guy Baril; Jonathan B Angel; M John Gill; Joseph Gathe; Pedro Cahn; Jean van Wyk; Sharon Walmsley
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

6.  Antiretroviral Drugs Alter the Content of Extracellular Vesicles from HIV-1-Infected Cells.

Authors:  Catherine DeMarino; Michelle L Pleet; Maria Cowen; Robert A Barclay; Yao Akpamagbo; James Erickson; Nicaise Ndembi; Manhattan Charurat; Jibreel Jumare; Sunday Bwala; Peter Alabi; Max Hogan; Archana Gupta; Nicole Noren Hooten; Michele K Evans; Benjamin Lepene; Weidong Zhou; Massimo Caputi; Fabio Romerio; Walter Royal; Nazira El-Hage; Lance A Liotta; Fatah Kashanchi
Journal:  Sci Rep       Date:  2018-05-16       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.